Articles in IPOs

Renaissance Capital

Synchrony Financial scheduled to enter the Renaissance IPO ETF (IPO)

Synchrony Financial ( SYF ), GE's private label credit card and consumer finance business, priced its IPO at $23. The gross proceeds of $2.9 billion make it the largest US IPO of the year.... Read >>

Renaissance Capital

Transocean Partners LLC prices IPO above the range at $22

Transocean Partners LLC, formed by Transocean ( RIG ) to own three ultra deepwater rigs in the Gulf of Mexico, raised $385 million by offering 17.5 million shares at $22, above the range of $19... Read >>

Renaissance Capital

FCB Financial Holdings decreases IPO shares and range

FCB Financial Holdings, a Florida based bank formed through acquisitions of eight failed banks, lowered the proposed deal size for its upcoming IPO on Thursday. The Weston, FL based company now... Read >>

Renaissance Capital

Cardiovascular diagnostics company Lantheus Holdings postpones IPO

Lantheus Holdings, which sells medical imaging agents used in the diagnosis of cardiovascular diseases, postponed its IPO on Wednesday, citing poor market conditions. The North Billerica, MA... Read >>

Renaissance Capital

Bio Blast Pharma prices IPO at $11, the low end of the range

Bio Blast Pharma, a biotech developing treatments for rare and ultra rare genetic diseases, raised $35 million by offering 3.2 million shares at $11, the low end of the range of $11 to $13. Bio... Read >>

Renaissance Capital

Vascular Biogenics prices IPO at $12, below the range

Vascular Biogenics, which is developing gene therapies for cancer and small molecules for inflammation, raised $65 million by offering 5.4 million shares at $12, below the range of $13 to $15.... Read >>

Renaissance Capital

HealthEquity prices IPO at $14, above the range

HealthEquity, which offers an integrated platform for managing Health Savings Accounts (HSAs), raised $127 million by offering 9.1 million shares at $14, above its $10 to $12 range. HealthEquity... Read >>

Renaissance Capital

Avalanche Biotechnologies prices upsized IPO at $17, the high end of the upwardly revised range

Avalanche Biotechnologies, an early stage biotech developing a gene therapy for wet AMD, raised $102 million by offering 6.0 million shares at $17, the high end of its upwardly revised $16 to... Read >>

Renaissance Capital

Catalent prices IPO at $20.50, midpoint of the range

Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, raised $871 million by offering 42.5 million shares (100% primary) at $20.50, the midpoint of the $19... Read >>

Renaissance Capital

Macrocure prices IPO well below the range at $10

Macrocure, an Israeli biotech developing white blood cell injections to treat hard to heal wounds, raised $54 million by offering 5.4 million shares (all primary) at $10, well below the range of... Read >>

Displaying 71-80 of 2611
<< first 8 9 10 11 12 50 100 150 200 250 last >>